Tetratherix Launches Precision Medicine Franchise, Signs $3 Million-a-Year Deal With Superpower Health

MT Newswires Live

Mar 16

Tetratherix (ASX:TTX)said it has launched a new precision medicine franchise leveraging its Tetramatrix platform polymer, according to a Monday Australian bourse filing.

The company said the franchise will be immediately revenue-generating via an exclusive research and development agreement with US consumer health group Superpower Health, which will pay Tetratherix an exclusive licence payment of $3 million per year for up to 10 years.

Under the agreement, Superpower will also purchase Tetramatrix platform polymer, branded as STEPP, for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides, and hormones in the US market, the filing added.

The company said the precision medicine franchise is entirely additive to its existing business, with revenue generated under the agreement expected to strengthen its cash position without diverting resources from core programs, which are funded through to the start of fiscal 2028.

Tetratherix continues to expect two FDA approvals in its bone regeneration franchise in mid-2026, the filing added.

The company's shares rose almost 28% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2619345326"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619345326\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619345326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619345326","market":"sh","top_or_hot":-1,"title":"Tetratherix Launches Precision Medicine Franchise, Signs $3 Million-a-Year Deal With Superpower Health","media":"MT Newswires Live","content":"<html><body><p> Tetratherix (ASX:TTX)said it has launched a new precision medicine franchise leveraging its Tetramatrix platform polymer, according to a Monday Australian bourse filing.</p><p>The company said the franchise will be immediately revenue-generating via an exclusive research and development agreement with US consumer health group Superpower Health, which will pay Tetratherix an exclusive licence payment of $3 million per year for up to 10 years.</p><p>Under the agreement, Superpower will also purchase Tetramatrix platform polymer, branded as STEPP, for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides, and hormones in the US market, the filing added.</p><p>The company said the precision medicine franchise is entirely additive to its existing business, with revenue generated under the agreement expected to strengthen its cash position without diverting resources from core programs, which are funded through to the start of fiscal 2028.</p><p>Tetratherix continues to expect two FDA approvals in its bone regeneration franchise in mid-2026, the filing added.</p><p>The company's shares rose almost 28% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tetratherix Launches Precision Medicine Franchise, Signs $3 Million-a-Year Deal With Superpower Health</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTetratherix Launches Precision Medicine Franchise, Signs $3 Million-a-Year Deal With Superpower Health\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-16 16:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tetratherix (ASX:TTX)said it has launched a new precision medicine franchise leveraging its Tetramatrix platform polymer, according to a Monday Australian bourse filing.</p><p>The company said the franchise will be immediately revenue-generating via an exclusive research and development agreement with US consumer health group Superpower Health, which will pay Tetratherix an exclusive licence payment of $3 million per year for up to 10 years.</p><p>Under the agreement, Superpower will also purchase Tetramatrix platform polymer, branded as STEPP, for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides, and hormones in the US market, the filing added.</p><p>The company said the precision medicine franchise is entirely additive to its existing business, with revenue generated under the agreement expected to strengthen its cash position without diverting resources from core programs, which are funded through to the start of fiscal 2028.</p><p>Tetratherix continues to expect two FDA approvals in its bone regeneration franchise in mid-2026, the filing added.</p><p>The company's shares rose almost 28% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2619345326","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619345326","pubTimestamp":1773650344,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tetratherix said it has launched a new precision medicine franchise leveraging its Tetramatrix platform polymer, according to a Monday Australian bourse filing.The company said the franchise will be immediately revenue-generating via an exclusive research and development agreement with US consumer health group Superpower Health, which will pay Tetratherix an exclusive licence payment of $3 million per year for up to 10 years.Under the agreement, Superpower will also purchase Tetramatrix platform polymer, branded as STEPP, for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides, and hormones in the US market, the filing added.The company said the precision medicine franchise is entirely additive to its existing business, with revenue generated under the agreement expected to strengthen its cash position without diverting resources from core programs, which are funded through to the start of fiscal 2028.Tetratherix continues to expect two FDA approvals in its bone","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TTX.AU":"Tetratherix Ltd"},"translate_title":"Tetratherix推出精准医疗特许经营权，与Superpower Health签署每年300万美元的协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TTX.AU":1},"content_text":"Tetratherix (ASX:TTX)said it has launched a new precision medicine franchise leveraging its Tetramatrix platform polymer, according to a Monday Australian bourse filing.The company said the franchise will be immediately revenue-generating via an exclusive research and development agreement with US consumer health group Superpower Health, which will pay Tetratherix an exclusive licence payment of $3 million per year for up to 10 years.Under the agreement, Superpower will also purchase Tetramatrix platform polymer, branded as STEPP, for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides, and hormones in the US market, the filing added.The company said the precision medicine franchise is entirely additive to its existing business, with revenue generated under the agreement expected to strengthen its cash position without diverting resources from core programs, which are funded through to the start of fiscal 2028.Tetratherix continues to expect two FDA approvals in its bone regeneration franchise in mid-2026, the filing added.The company's shares rose almost 28% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}